$ELOX

SENESCO TECHNOLOGIES INC

CIK:0001035354|SEC Filings

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 2,840	$ 898	$ 4,500	$ 1,408
General and administrative	1,610	684	3,746	1,396
Total operating expenses	4,450	1,582	8,246	2,804
Loss from operations	(4,450)	(1,582)	(8,246)	(2,804)
Other expense, net	52	309	10	796
Net loss	$ (4,502)	$ (1,891)	$ (8,256)	$ (3,600)
Net loss per share, basic	$ (0.66)	$ (5.45)	$ (1.48)	$ (10.39)
Net loss per share, diluted	$ (0.66)	$ (5.45)	$ (1.48)	$ (10.39)
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic	6,789,165	347,000	5,592,596	346,482
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, diluted	6,789,165	347,000	5,592,596	346,482

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)
Cash flows from operating activities:
Net loss			$ (8,256)	$ (3,600)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			141	36
Amortization of debt discount			15	236
Gain on extinguishment of accrued interest	$ 0	$ 0	(56)	0
Imputed interest expense on 2025 bridge loans	0	112	0	137
Change in fair value of warrant liabilities	62	0	62	0
Changes in operating assets and liabilities:
License fee receivable			0	2,359
Unbilled receivable			0	359
Prepaid expenses and other current assets			(943)	(294)
Accounts payable			(467)	(475)
Accrued expenses			(759)	315
Accrued interest			21	378
Net cash (used in) provided by operating activities			(10,242)	(549)
Cash flows from financing activities:
Proceeds from the June 2026 public offering, net of issuance costs			60,295	0
Proceeds from issuance of pre-funded warrants under the Coastlands and Domicilium Securities Purchase Agreements, net of issuance costs			6,991	0
Repayment of term loan principal			0	(1,255)
Proceeds from debt financing obligations			0	2,265
Exercise of pre-funded warrants	91		91	0
Exercise of stock options			40	0
Net cash provided by (used in) financing activities			67,417	1,010
Increase in cash, cash equivalents and restricted cash			57,175	461
Cash, cash equivalents and restricted cash at the beginning of the period			4,791	116
Cash, cash equivalents and restricted cash at the end of the period	61,966	577	61,966	577
Reconciliation of cash, cash equivalents and restricted cash to condensed consolidated balance sheets:
Cash and cash equivalents	61,960	572	61,960	572
Restricted cash	6	5	6	5
Total cash, cash equivalents and restricted cash	$ 61,966	$ 577	61,966	577
Supplemental disclosure of cash flow activities:
Cash paid for interest			0	40
Noncash financing activities:
Domicilium debt conversion and waiver of accrued interest, (principal of $1,000 and accrued interest of $56			1,056	0
Issuance costs in accounts payable and accrued expenses			$ 1,975	$ 0

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 61,960	$ 4,785
Restricted cash	6	6
Prepaid expenses and other current assets	1,422	479
Total current assets	63,388	5,270
Total assets	63,388	5,270
Current liabilities:
Accounts payable	3,028	2,713
Accrued expenses	2,047	1,613
Advances from collaboration partners, net of debt discount	11,831	11,816
Current portion of long-term debt	0	1,000
Accrued interest on debt	0	35
Warrant liabilities	62	0
Total current liabilities	16,968	17,177
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued or outstanding as of June 30, 2026 and December 31, 2025	0	0
Common stock, $0.01 par value per share, 100,000,000 and 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively, 4,036,398 and 435,432 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	40	4
Additional paid-in capital	355,216	288,669
Accumulated deficit	(308,836)	(300,580)
Total stockholders' equity (deficit)	46,420	(11,907)
Total liabilities and stockholders' equity (deficit)	$ 63,388	$ 5,270